Martin Shkreli Reveals How He Made His First $100 Million

Author

Joshua Clear
May 12, 2025

In partnership with

Global payroll complexity? Here’s the playbook.

Managing global payroll shouldn’t mean juggling vendors and compliance risks. Deel, recognized in the Gartner® Market Guide for Multicountry Payroll Solutions, helps finance teams automate payments, standardize reporting, and stay compliant in 100+ countries. Get key insights from industry experts to future-proof your payroll strategy.

Martin Shkreli – AKA “Pharma Bro,” the man who went from hedge fund kid to Pharma villain to prison inmate…and now? An unapologetically sharp biotech entrepreneur with billion-dollar biotech wins and a brand-new AI startup. Whether you think he’s a capitalist monster or misunderstood genius, he’s got insights you can’t afford to ignore.

🎙️ EPISODE SNAPSHOT

Strap in: This episode is a rollercoaster through hedge funds, biotech arbitrage, and PR nightmares. Martin spills how he actually made his first $100M—not from jacking up drug prices, but by playing chess while others were playing checkers in pharma investing. Plus, he drops 🔥 takes on corporate CEOs, the healthcare system, and the AI startup he's quietly building.

💡 KEY TAKEAWAYS

1. The goldmine is hidden in public databases.
Martin Shkreli credits much of his pharmaceutical success to relentless deep-diving into PubMed, a free government database with over 36 million biomedical research papers. He treated it like Wall Street treated Bloomberg terminals — obsessively combing through studies to find promising drug compounds that others missed. His bet? If you’re willing to sift through thousands of research abstracts and connect dots better than pharma execs, you’ll eventually find billion-dollar drugs hiding in plain sight.

2. Hedge funds ≠ guaranteed riches.
Contrary to the flashy narrative, Shkreli made no real money from running hedge funds. He even refused to take fees from his investors and admits he lacked the temperament for the business side of managing capital. His real financial breakthrough came when he transitioned from trader to operator — owning pharma assets instead of merely investing in them.

3. Most CEOs play it safe—and lose.
Martin threw major shade at today's corporate culture, especially CEOs who live in fear of saying the wrong thing. He argues that vanilla leadership leads to stagnant businesses, and the obsession with PR-safe language strangles innovation. His advice? Don’t be afraid to challenge norms and make uncomfortable but high-conviction decisions — because that’s where the alpha lives.

4. Pharma is the long game.
Unlike tech startups that can scale overnight, pharma is a marathon. The drug that made him rich — sparsentan — took over a decade to get FDA approval. What’s wild is he cashed out before the product ever reached shelves, proving that early conviction and validation can be enough to capture massive value before outcomes even materialize.

5. He didn’t go to jail for drug pricing.
Despite the media’s fixation on his infamous Daraprim price hike, that’s not what landed him in prison. Shkreli was convicted on unrelated charges tied to misleading hedge fund investors. While his smug persona may have hurt his public image, the legal charges were about financial disclosure — not pharmaceutical ethics.

🛠️ TOOLS, WEBSITES, RESOURCES MENTIONED

1. PubMed
This is the U.S. National Library of Medicine's open-access treasure trove. Shkreli used it as his competitive intelligence engine, reading obscure medical papers to discover promising drugs that big pharma had abandoned. It’s the ultimate underdog weapon — zero cost, infinite upside for those with time and intellectual stamina.

2. Fidelity
Not so much a tool as a flex. Shkreli casually mentioned he had $60M sitting in his Fidelity account at one point, highlighting just how capital-intensive his game got after his initial wins. It also reveals how much liquidity (or lack thereof) matters when you’re asset-rich but cash-poor.

3. Reverse Merger Strategy
He took his pharma company public using a reverse merger — a backdoor way to hit public markets without a traditional IPO. In biotech, this move can be a power play: skip the regulatory circus, raise capital faster, and ride investor hype based on pipeline assets. High risk, but also potentially high speed to liquidity.

💼 BUSINESS IDEAS & OPPORTUNITIES

1. Biotech Arbitrage
Find undervalued or "orphaned" assets that big pharma ditched — not because they don’t work, but because they don’t fit the portfolio. Shkreli turned one such $2M licensing deal into a billion-dollar valuation by repositioning the asset for a niche kidney disease. If you’ve got the research chops, the ROI here is insane.

2. AI x Healthcare
Martin hinted at a stealth-mode AI startup aimed at drug development. With models like AlphaFold cracking protein folding and LLMs speeding up research, this is a mega-trend to watch. The opportunity? Build tools that connect biomedical data, regulatory compliance, and AI-assisted molecule design.

3. Search-to-Riches
He made it clear: most people are lazy. If you're willing to dig deep — into PubMed, patents, clinical trial data — there's a frontier of overlooked business opportunities. The competitive moat here isn’t money — it’s obsession.

🔧 LIFE HACKS

1. “Just read more than everyone else.”
Shkreli claims that the ability to become a billionaire is directly correlated with your willingness to sit and read for hours. He believes all the world’s secrets are hidden in dry research — but no one has the patience to decode them. So the hack? Out-learn your competition until you're the one seeing patterns no one else notices.

2. Forget college, follow obsession.
He was already knee-deep in hedge fund work while still technically in high school. For him, curiosity and raw ambition beat diplomas. If you're a young person debating dropping out for a startup — make sure you're obsessed, not just bored.

🤑 BEST IDEAS FOR FASTEST MONEY

1. Acquiring undervalued drug IP.
Big pharma often shelves drugs for reasons unrelated to their efficacy. If you can find one with promising Phase 1 or 2 data, you can license it cheap and build a startup around it. Shkreli’s $2M deal turned into a $1B company — before FDA approval.

2. Mastering public databases like PubMed.
This isn’t just a nerd flex. If you can reverse-engineer a drug pipeline from public research, you essentially front-run pharma investors and analysts. No paywall, no gatekeeping — just brutal mental stamina.

3. Reverse mergers in niche sectors.
Skip the costly IPO slog. Shkreli used reverse mergers to get his company public fast, raise capital, and validate its valuation. Particularly powerful in biotech, where the story is often more valuable than actual product revenue in early stages.

  • 36 million+ articles on PubMed: Virtually every biomedical advancement ever is documented here — a DIY R&D lab for ambitious autodidacts.

  • $2M to $1B pharma play: He bought an abandoned asset and repositioned it with a new clinical focus, showing the power of strategic reframing.

  • $1.5B valuation pre-FDA: Shkreli’s company hit unicorn status without even launching its product — a testament to investor appetite for good storytelling backed by research.

🔑 ACTIONABLE STRATEGIES

1. Become a data detective.
Use PubMed like a financial model. Find promising compounds, understand mechanisms of action, and map them to diseases pharma ignores. Build conviction through real research, not Reddit threads.

2. License strategically, not sentimentally.
Negotiate rights to drugs that are "orphans" in large portfolios. Pharma companies often offload these cheaply if you can frame a clear use case and a compelling path to approval.

3. Use reverse mergers to build momentum.
Especially in sectors like biotech or clean energy, speed-to-market is often more valuable than polish. Go public fast, use your stock as currency, and raise your profile to attract bigger funding rounds.

4. Be polarizing — strategically.
Martin’s anti-PR stance isn’t just edgy branding; it’s a calculated differentiation play. In a sea of “safe” CEOs, being brutally transparent (even if disliked) can attract a tribe of high-conviction supporters and investors.

📉 EXTERNAL FACTORS

1. Economic Climate & Funding Pressure:
Shkreli’s early days in biotech overlapped with the 2008 financial crisis, a time when capital was scarce and risk aversion was high. This environment made it easier for scrappy operators to scoop up undervalued assets from distracted or distressed sellers.

2. Regulatory Terrain (FDA & FTC):
The pharmaceutical industry is notoriously slow-moving due to FDA approval timelines. Shkreli leaned into this friction, buying pre-approval assets at a discount and arbitraging their future potential. On the flip side, he later became the first individual personally sued under the Sherman Antitrust Act by the FTC — a landmark moment signaling increased regulatory scrutiny of “monopoly-like” behavior in pharma.

3. Healthcare Consumer Behavior:
Shkreli emphasized that healthcare spending behaves irrationally compared to typical consumer goods. Patients and insurers treat life-saving drugs as “must-haves” regardless of cost, which makes pricing elastic and emotionally charged — and why price hikes trigger media firestorms even when no patient access is lost.

4. Competitive Dynamics in Pharma:
Big pharma firms often abandon promising compounds that don’t align with their “strategic portfolio.” Shkreli exploited this by hunting down those cast-offs, acquiring them cheaply, and repositioning them for smaller, overlooked disease markets. He refers to this as pharma arbitrage — taking advantage of big players' bureaucracy and quarterly thinking.

📈 BUSINESS METRICS (FROM THE EPISODE)

  • $2M → $1B: The most eye-popping figure. Shkreli acquired a forgotten drug asset for $2 million and built a company around it that eventually reached a ~$1 billion valuation pre-FDA approval.

  • $1.5B: Valuation of his company Traver (formerly Retrophin) when it went public.

  • Ownership trajectory: He began with 90% equity, which diluted to 15–20% by IPO time — showing how cap tables shift as funding rounds stack.

  • $60M: Amount he had sitting in a Fidelity account during the height of his wealth — just one piece of his net worth.

  • $8M: Total criminal fines he had to pay — which he covered easily, partly by selling the Wu-Tang Clan’s one-of-a-kind album during the NFT boom.

  • $60M FTC judgment: A civil antitrust penalty that he’s appealing; this lawsuit represents a massive personal financial liability and a key risk factor for future ventures.

1. Shift from Hedge Funds to Ownership
Shkreli argues the hedge fund game is dying — regulatory risk, short fund lifespans, and no value creation are pushing smart capital toward private equity-style business building.

2. The Rise of Deep Diligence Entrepreneurs
The new wave of operators isn’t following passion — they’re reverse-engineering high ROI plays from data. Shkreli exemplifies the trend of founders who begin with assets (e.g., drugs, tech IP) and build backward into a company.

3. Public Market Arbitrage in Biotech
Early-stage biotech companies can achieve billion-dollar valuations before revenue or FDA approval. The market overweights potential over performance — a key asymmetry he used to his advantage via reverse mergers.

4. Healthcare Spending as a Macro Megatrend
He predicts U.S. healthcare spending will balloon from 20% to 50% of GDP as society increasingly prioritizes longevity and quality of life. This macro tailwind makes pharma a perpetual growth sector — albeit a heavily regulated one.

🚀 BUSINESS INITIATIVES (Shkreli’s Playbook)

1. Drug Repositioning & Licensing Strategy
Buy forgotten or underfunded pharma assets from major firms and re-engineer them for smaller disease niches. He did this with sparsentan, a drug originally intended for hypertension, which he pivoted toward kidney disease.

2. Reverse Merger for IPO Access
Instead of the traditional IPO grind, he used a “SPAC before SPACs were cool” method: reverse merging into an existing public shell to raise capital and hit public markets faster.

3. New AI Startup (Unveiled Quietly)
Shkreli revealed plans for a startup in the AI + drug discovery space. While details were vague, he emphasized it as a pivot toward more ethical, scalable, and tech-forward biotech business models.

4. Positioning as the Anti-Corporate CEO
His personal brand — anti-vanilla, unfiltered, confrontational — is a deliberate tactic to attract contrarian investors and loyal believers. He sees the stiff, sterile CEO archetype as obsolete.

🔮 FORWARD-LOOKING STATEMENTS

1. “I’ll make another hundred million easily.”
Shkreli exudes confidence that even if he loses his entire fortune, he can rebuild quickly. His logic? Talent, asymmetric insight, and capital discipline are replicable formulas.

2. Healthcare to become 50% of GDP.
He predicts U.S. healthcare will consume half of GDP in the next few decades as consumers demand more medical innovation, longevity solutions, and health-as-status. This underpins his bet on biotech and drug platforms.

3. AI x Pharma as his next empire.
His future focus is building tools that can help automate drug discovery and development, tapping into the generational wave of AI’s impact on R&D-heavy industries.

4. “I want to make things right.”
Somewhat surprisingly, he alluded to the new company being partially “penance” for his past — potentially signaling a shift toward more ethically-grounded operations and investor narratives.